Clairity has received FDA de novo authorization for Clarity Breast, an AI tool that predicts five-year breast cancer risk from screening mammograms.
Key Details
- 1Clairity Breast predicts future breast cancer risk using AI analysis of 2D screening mammograms.
- 2FDA de novo authorization has been granted for the software platform.
- 3The AI model was trained on 450,000+ mammograms and validated on 77,000 exams with five-year follow-up data.
- 4Unlike CAD tools, the software provides a risk percentage for patients rather than assisting real-time interpretation.
- 5Models were developed for diverse populations, addressing historic limitations in risk prediction for non-European ancestry.
- 6Currently available for Hologic mammography systems, with future plans for multivendor and 3D support.
Why It Matters
This represents a significant advance in leveraging mammogram images beyond immediate diagnosis, opening new avenues for personalized risk assessment in breast imaging. The FDA clearance and focus on diversity in model training mark meaningful steps toward broader clinical adoption and equity.
Source
AuntMinnie
Related News
•Radiology Business
Framework Assesses Real-World Financial Impact of Radiology AI Adoption
A new analysis presents a financial calculator for objectively assessing the return on investment (ROI) of implementing radiology AI solutions.
•Radiology Business
Radiology Dominates FDA AI Algorithm Clearances in 2026
Radiology accounted for 68 new FDA-cleared AI algorithms in early 2026, making up more than three-quarters of all AI clinical clearances.
•Radiology Business
Private Equity Backs AIRS Medical to Expand MRI AI Globally
TA Associates is investing in AIRS Medical to accelerate its global expansion of AI-powered MRI efficiency solutions.